Chart: Should Medicare Cover Menaflex?
This article was originally published in The Gray Sheet
When CMS began a coverage review for ReGen Biologics' Menaflex collagen meniscus implant on Aug. 27, it declined to say whether the internally generated action was related to the FDA controversy over the product ("The Gray Sheet" Aug. 31, 2009). Numerous commenters expressed surprise that CMS would consider Medicare coverage for a product not intended for and never studied in patients age 65 and older, and point out that a negative coverage decision could influence other insurers not to cover younger patients who might benefit from the device. Key comments, which were due Sept. 26, are excerpted below.
You may also be interested in...
ReGen Biologics' Menaflex knee meniscus device is now under scrutiny at two government agencies
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.